Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients without insurance or with high-deductible coverage.
The drugmaker says it will make available in the next several weeks a generic EpiPen version that is identical to the branded option but will have a list price of $300 for a two-pack.
It will be available in both 0.15-milligram and 0.30-milligram strengths, like the current version on the market.
EpiPens are used in emergencies to treat severe allergies to insect bites and foods like nuts and eggs that can lead to anaphylactic shock. People usually keep a number of EpiPens handy at home, school or work. The syringes, prefilled with the hormone epinephrine, expire after a year.
Consumers and politicians have accused the company of price-gouging, since the list price for a pair of EpiPens has climbed repeatedly from around $94 in 2007, when Mylan acquired the product.
Mylan NV CEO Heather Bresch defended the price hikes last week, saying the company only received $274 of the total price ...